Items tagged with Treatment
Statement from The Union on bedaquiline access, India (post)
Paris, France, 19 January 2017– Drug-resistant TB is one of the most terrible diseases that any person can ever face. Even when treatment is effective, it is long and very difficult. The health system must do everything in its power to provide access to effective treatments for every patient, with the appropriate treatment depending on the drug susceptibility profile involved in each case. It is essential that drug-sensitivity testing be performed at the outset, so that healthcare workers and patients know which medicines are likely to be effective in treatment and which will not be effective due to resistance. People living with drug-resistant TB should receive only those TB medicines that are likely to be effective in the case of that patient, and they must be treated with multiple medicines, at the same time, to which the TB is susceptible—a treatment approach known as “combination therapy”.
New TB therapy could be more potent than current treatments (post)
Taking a new approach toward tuberculosis therapy, a UCLA-led research team has devised a potential drug regimen that could cut the treatment time by up to 75 percent, while simultaneously reducing the risk that patients could develop drug-resistant TB.
Drug regimens identified and optimized by output-driven platform markedly reduce TB treatment time (post)
Abstract
U.S. government introduces new drug to help save lives of TB patients in Tajikistan (post)
Acting Deputy Chief of Mission of the United States to Tajikistan Lucy Jilka yesterday (January 31) joined the First Deputy Minister of Health and Social Protection of Population of Tajikistan Saida Umarzoda, national health leadership, physicians, TB doctors, and stakeholders to celebrate the introduction of bedaquiline to Tajikistan. This is the first new drug approved for the treatment of tuberculosis (TB) since the 1960s.
Treatment of isoniazid-resistant TB with first-line drugs: a systematic review and meta-analysis (post)
Summary
Fixed drug combinations for TB rolled out in Mumbai (post)
MUMBAI: The BMC on Monday (February 6) rolled out fixed dose combinations for patients of drug-sensitive tuberculosis, which will not only reduce the pill burden but also increase their adherence to treatment. This also marks a significant shift in the Directly Observed Treatment Short-course (DOTS) programme, where a patient used to be administered the medicines thrice a week under the supervision of a doctor.
Survival of people living with HIV who defaulted from TB treatment in a cohort, Recife, Brazil (post)
Abstract
Study confirms key therapeutic advance for children living with HIV and TB (post)
[Seattle, USA, February 14, 2017] The non-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) has released results of a study in South Africa that will make it easier for healthcare workers to treat children living with HIV who are co-infected with tuberculosis (TB). The study, presented as a late-breaker this week at the Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, provides essential evidence and data to counter the negative interactions between two critical HIV and TB treatments.
Page 28 of 108 · Total posts: 0
←First 27 28 29 Last→